Clinical trials: Newly Diagnosed Multiple Myeloma
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Trial name
- NCT04653246
- Testing
- Isatuximab, Lenalidomide, Bortezomib Injection
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jacob Laubach, MD
Myeloma Multiple
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
- Trial name
- NCT05091372
- Testing
- Belantamab mafodotin, Lenalidomide
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
This research study is explore the impact over time of multiple myeloma and its associated treatments on the physical and cognitive function and quality of life of patients and their care partners and how these impacts affect the…
- Trial name
- PaCE-MM (NCT05276622)
- Testing
- Comprehensive Geriatric Assessment, Qualitative patient-care partner interviews, Surveys on well-being and function
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center